IMMUNE CHECKPOINT INHIBITORS MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

  2024-11-27 |   Pages: 200+ |   Report ID: MD-R-2024-11-27-141535 |   Health Care

Historical data: 2018 - 2023

Forecast period: 2024 - 2031

Quantitative units: Revenue in USD million and CAGR from 2024 to 2031

Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Immune Checkpoint Inhibitors Market

Image

1.1 SCOPE OF THE REPORT

1.2 MARKET SEGMENT ANALYSIS

1.3 REGULATORY SCENARIO BY REGION/COUNTRY

1.4 MARKET INVESTMENT SCENARIO STRATEGIC

1.5 MARKET ANALYSIS BY TYPE (USD MILLION)

1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET

7.1 GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE AND SHARE (2018-2031) (USD MILLION)

8.1 GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

8.2 GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

9.1 GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

9.2 GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

10.1 GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)

10.2 GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)

11.1 NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

11.2 NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

11.3 NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

11.4 NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

11.5 NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

11.6 NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

12.1 EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

12.2 EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

12.3 EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

12.4 EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

12.5 EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

12.6 EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

13.1 ASIA PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

13.2 ASIA PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

13.3 ASIA PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

13.4 ASIA PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

13.5 ASIA PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

13.6 ASIA PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

14.1 LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>

14.2 LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

14.3 LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

14.4 LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

14.5 LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

14.6 LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>

16.1 Bristol Myer Squibb (United States)

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 AstraZeneca plc (United Kingdom)

16.3 Merck & Co. (United States)

16.4 F. Hoffmann-La Roche AG (Switzerland)

16.5 Incyte Corporation (United States)

16.6 NewLink Genetics (United States)

16.7 ArGEN-X (Netherlands)

16.8 Seagen Inc. (United States)

16.9 Pfizer Inc. (United States)

16.10 MacroGenics (United States)

16.11 Celldex Therapeutics (United States)

16.12 Immutep Ltd (Australia)

16.13 Innate Pharma (France)

16.14 Sorrento Therapeutics (United States)

16.15 GlaxoSmithKline (United Kingdom)

16.16 GITR, Inc (United States)

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER

Market Segments

By Type
CTLA-4 Inhibitor
PD-1 Inhibitor
PD-L1 Inhibitor
By Application
Melanoma
Lung Cancer
Urothelial Carcinoma
Hodgkin Lymphoma
Squamous Cell Carcinoma
Blood Cancer
Others
By Route of Administration
Oral
Parenteral
Others

By Distribution Channel
Retail Pharmacies
Hospital Pharmacies

By End User
Hospitals
Specialty Clinics
Others

Companies

Bristol Myer Squibb (United States)
AstraZeneca plc (United Kingdom)
Merck & Co. (United States)
F. Hoffmann-La Roche AG (Switzerland)
Incyte Corporation (United States)
NewLink Genetics (United States)
ArGEN-X (Netherlands)
Seagen Inc. (United States)
Pfizer Inc. (United States)
MacroGenics (United States)
Celldex Therapeutics (United States)
Immutep Ltd (Australia)
Innate Pharma (France)
Sorrento Therapeutics (United States)
GlaxoSmithKline (United Kingdom)
GITR, Inc (United States)

Single User License  : 3900$
Corporate License    : 7800$
Enquiry Before Buying
Request For Customization
Speak To Analyst

BROWSE INDUSTRY

  1. Consumer Goods
  2. Healthcare
  3. Food & Beverage
  4. Heavy Industry
  5. Service Industries
  6. FMCG
  7. Life Sciences
  8. Technology & Media
  9. Machinery & Equipment

    WHY CHOOSE US

  •   PROACTIVE

    • We manage our resources 24/7 to identify issues and address them before they become problems.

  •   QUALITY & RELIABILITY

    • We are committed to providing reliable and highly accurate data with an excellent quality control system.

  •   GLOBAL OUTREACH

    • 6 Major regions and 40+ countries level analysis accomplished.

  •   COMPETITIVE PRICING

    • Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.